Stock CHRS COHERUS BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-12 pm EDT 		5-day change 1st Jan Change
1.82 USD +5.20% Intraday chart for Coherus BioSciences, Inc. +0.55% -45.35%
Jun. 07 AbbVie's tight grip on Humira market raises concerns about biosimilars RE
Jun. 05 Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AbbVie's tight grip on Humira market raises concerns about biosimilars
RE
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
GL
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
AQ
Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors
CI
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
GL
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 Antibody, CHS-114, at the 2024 American Society of Clinical Oncology Annual Meeting
CI
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
GL
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
AQ
Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating
MT
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Transcript : Coherus BioSciences, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, vs. Street Est of $83.8M
MT
Coherus BioSciences: Q1 Earnings Snapshot
AQ
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Coherus BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI with ENB Therapeutics ENB-003 for the Treatment of Ovarian Cancer
AQ
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
GL
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
AQ
Coherus Biosciences, Inc. Enters into a Senior Secured Term Loan Facility
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CHRS Stock
  4. News Coherus BioSciences, Inc.